FR2816943B1 - Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs - Google Patents

Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs

Info

Publication number
FR2816943B1
FR2816943B1 FR0015049A FR0015049A FR2816943B1 FR 2816943 B1 FR2816943 B1 FR 2816943B1 FR 0015049 A FR0015049 A FR 0015049A FR 0015049 A FR0015049 A FR 0015049A FR 2816943 B1 FR2816943 B1 FR 2816943B1
Authority
FR
France
Prior art keywords
vectors
methods
making same
biotin derivatives
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0015049A
Other languages
English (en)
Other versions
FR2816943A1 (fr
Inventor
Abdelakim Kharrat
Khalil Bouayadi
Jean Charles Faye
Emmanuelle Fourcade
Rudi Baron
Daniel Tovar
Casimir Blonski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR0015049A priority Critical patent/FR2816943B1/fr
Priority to EP01997495A priority patent/EP1347985A2/fr
Priority to AU2002222004A priority patent/AU2002222004A1/en
Priority to PCT/FR2001/003669 priority patent/WO2002042311A2/fr
Priority to US10/432,383 priority patent/US20040138446A1/en
Publication of FR2816943A1 publication Critical patent/FR2816943A1/fr
Application granted granted Critical
Publication of FR2816943B1 publication Critical patent/FR2816943B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/185Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system
    • C12P17/186Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system containing a 2-oxo-thieno[3,4-d]imidazol nucleus, e.g. Biotin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0015049A 2000-11-22 2000-11-22 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs Expired - Fee Related FR2816943B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0015049A FR2816943B1 (fr) 2000-11-22 2000-11-22 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs
EP01997495A EP1347985A2 (fr) 2000-11-22 2001-11-21 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs
AU2002222004A AU2002222004A1 (en) 2000-11-22 2001-11-21 Biotin derivatives, methods for making same and uses thereof as vectors
PCT/FR2001/003669 WO2002042311A2 (fr) 2000-11-22 2001-11-21 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs
US10/432,383 US20040138446A1 (en) 2000-11-22 2001-11-21 Biotin derivatives, methods for making same and uses thereof as vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0015049A FR2816943B1 (fr) 2000-11-22 2000-11-22 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs

Publications (2)

Publication Number Publication Date
FR2816943A1 FR2816943A1 (fr) 2002-05-24
FR2816943B1 true FR2816943B1 (fr) 2004-02-13

Family

ID=8856739

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0015049A Expired - Fee Related FR2816943B1 (fr) 2000-11-22 2000-11-22 Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs

Country Status (5)

Country Link
US (1) US20040138446A1 (fr)
EP (1) EP1347985A2 (fr)
AU (1) AU2002222004A1 (fr)
FR (1) FR2816943B1 (fr)
WO (1) WO2002042311A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002097197A (ja) * 2000-07-18 2002-04-02 Yanaihara Kenkyusho:Kk エストラジオール誘導体およびこれを使用した測定法
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
EP2324076B1 (fr) 2008-07-31 2017-11-01 3M Innovative Properties Company Compositions à base de fluoropolymère et leur procédé de fabrication et d utilisation
EP2315802A4 (fr) * 2008-07-31 2012-04-18 3M Innovative Properties Co Compositions d'azoture et leurs procédés de préparation et d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601956B1 (fr) * 1986-07-22 1989-11-03 Pasteur Institut Nouveaux derives de desoxy-2' adenosine, leur procede d'obtention par voie de synthese et leurs applications biologiques
US5252743A (en) * 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
AU6886791A (en) * 1989-11-13 1991-06-13 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5128476A (en) * 1991-02-20 1992-07-07 The Midland Certified Reagent Company Biotinylated oligonucleotides and reagents for preparing the same
DE69434520T3 (de) * 1993-07-30 2009-10-15 Affymax, Inc., Palo Alto Biotinylierung von proteinen
FR2717499B1 (fr) * 1994-03-17 1996-05-24 Ulp Fragments d'anticorps recombinants synthétisés et biotinylés dans E. coli, leur utilisation en immunodosages et en purification par immunoaffinité.
GB9900298D0 (en) * 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
US6242610B1 (en) * 1999-05-27 2001-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Derivatized biotin compounds and methods of use
ATE356874T1 (de) * 1999-12-22 2007-04-15 Dade Behring Marburg Gmbh Lösungen von humanem procalcitonin

Also Published As

Publication number Publication date
FR2816943A1 (fr) 2002-05-24
EP1347985A2 (fr) 2003-10-01
WO2002042311A2 (fr) 2002-05-30
AU2002222004A1 (en) 2002-06-03
WO2002042311A3 (fr) 2002-09-19
US20040138446A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
FR20C1039I2 (fr) Derives de l'uk-2a
MA26932A1 (fr) Derives d'imidazole.
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
FR2806720B1 (fr) Derives de 2,2,6,6-diethyl-dimethyl-1-alcoxypiperidines et 1-oxydes correspondants
ATE368101T1 (de) Wäschereiprodukt
DE60125328D1 (de) Feuerwehrbekleidung
ATE473095T1 (de) Herstellung von wiederverschliessbaren verpackungen mit reissverschluss
BR0110814B1 (pt) método de produção de costuras laterais passìveis de serem fechadas novamente em uma vestimenta absorvente.
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
DE29809075U1 (de) Dynamischer, displayartiger Schmuckgegenstand
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
DE60130046D1 (de) Knotenauswahlverfahren
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
FR2816943B1 (fr) Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs
DE60138271D1 (de) Herstellung von DIBENZOÄB,FÜAZEPINE ZWISCHENPRODUKTE
DK1538150T3 (da) Hidtil ukendte pleuromultilinderivater
ATA75499A (de) Halbleiter-simulationsverfahren
FR2776485B1 (fr) Article chaussant isothermique
NO20024960D0 (no) Polyamidnukleinsyrederivater, midler og fremgangsmåter for fremstilling av disse
DZ3344A1 (fr) Derives de sulfonamide
DE60200082D1 (de) Kreuzgekoppelter Differenzverstärker
EE200200389A (et) Imidasooli uued derivaadid
DE60122295D1 (de) Flavon derivate, verfahren zu deren herstellung und deren verwendung als heilmittel
NO20030663D0 (no) Kartong og innsats, samt emne for dannelse av samme

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060731